These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11020126)

  • 1. Serum vitamin B6 in schizophrenic and schizoaffective patients with and without tardive dyskinesia.
    Miodownik C; Lerner V; Cohen H; Kotler M
    Clin Neuropharmacol; 2000; 23(4):212-5. PubMed ID: 11020126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia.
    Miodownik C; Meoded A; Libov I; Bersudsky Y; Sela BA; Lerner V
    Clin Neuropharmacol; 2008; 31(4):197-203. PubMed ID: 18670243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High serum homocysteine levels in young male schizophrenic and schizoaffective patients with tardive parkinsonism and/or tardive dyskinesia.
    Lerner V; Miodownik C; Kaptsan A; Vishne T; Sela BA; Levine J
    J Clin Psychiatry; 2005 Dec; 66(12):1558-63. PubMed ID: 16401157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study.
    Lerner V; Miodownik C; Kaptsan A; Cohen H; Loewenthal U; Kotler M
    J Clin Psychiatry; 2002 Jan; 63(1):54-8. PubMed ID: 11838627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study.
    Lerner V; Kaptsan A; Miodownik C; Kotler M
    Clin Neuropharmacol; 1999; 22(4):241-3. PubMed ID: 10442256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders].
    Miodownik C; Cohen H; Kotler M; Lerner V
    Harefuah; 2003 Sep; 142(8-9):592-6, 647. PubMed ID: 14518160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose vitamin B6 decreases homocysteine serum levels in patients with schizophrenia and schizoaffective disorders: a preliminary study.
    Miodownik C; Lerner V; Vishne T; Sela BA; Levine J
    Clin Neuropharmacol; 2007; 30(1):13-7. PubMed ID: 17272965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High plasma clozapine levels in tardive dyskinesia.
    Pollack S; Lieberman J; Kleiner D; Szymanski S; Kane J; Borenstein M; Cooper T
    Psychopharmacol Bull; 1993; 29(2):257-62. PubMed ID: 8290674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.
    Glazer WM; Morgenstern H; Schooler N; Berkman CS; Moore DC
    Br J Psychiatry; 1990 Oct; 157():585-92. PubMed ID: 1983390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia.
    Yang YQ; Sun S; Yu YQ; Li WJ; Zhang X; Xiu MH; Chen DC; De Yang F; Liu H; Li C; Kosten TR; Zhang XY
    Neurosci Lett; 2011 Sep; 502(1):37-40. PubMed ID: 21798311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study.
    Lerner V; Bergman J; Statsenko N; Miodownik C
    J Clin Psychiatry; 2004 Nov; 65(11):1550-4. PubMed ID: 15554771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.
    Csernansky JG; Kaplan J; Holman CA; Hollister LE
    Psychopharmacology (Berl); 1983; 81(2):115-8. PubMed ID: 6138793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements.
    Tan YL; Zhou DF; Zhang XY
    Schizophr Res; 2005 May; 74(2-3):263-70. PubMed ID: 15722005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial occurrence of tardive dyskinesia.
    Müller DJ; Schulze TG; Knapp M; Held T; Krauss H; Weber T; Ahle G; Maroldt A; Alfter D; Maier W; Nöthen MM; Rietschel M
    Acta Psychiatr Scand; 2001 Nov; 104(5):375-9. PubMed ID: 11722319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The natural history of tardive dyskinesia.
    Gardos G; Cole JO; Haskell D; Marby D; Paine SS; Moore P
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):31S-37S. PubMed ID: 2906068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological determinants and risk factors for tardive dyskinesia in schizophrenia.
    Sandyk R
    Int J Neurosci; 1993; 69(1-4):35-51. PubMed ID: 7916008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Nithsdale Schizophrenia Surveys. XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects.
    McCreadie RG; MacDonald E; Wiles D; Campbell G; Paterson JR
    Br J Psychiatry; 1995 Nov; 167(5):610-7. PubMed ID: 8564316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study.
    Lerner V; Miodownik C; Kaptsan A; Bersudsky Y; Libov I; Sela BA; Witztum E
    J Clin Psychiatry; 2007 Nov; 68(11):1648-54. PubMed ID: 18052557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.